Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 3 , Pages 336-338 , March 2010

Antimicrobial susceptibility of multidrug-resistant Streptococcus pneumoniae strains with penicillin MICs of 8 to 32 mg/L

Received 23 July 2009 ,Accepted 22 October 2009.

References 

  1. Arathoon EG, Hamilton JR, Hench CE, Stevens DA. Efficacy of short courses of oral novobiocin–rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrob. Agents Chemother. 1990;34:1655–1659
  2. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 18th informational supplement (M100-S18). Wayne, PA: CLSI; 2008;
  3. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob. Agents Chemother. 1986;30:42–45
  4. Eliopoulos G, Moellering RCJ. Antimicrobial combinations. In:  Lorian V editors. Antibiotics in laboratory medicine. Baltimore: The Williams & Wilkins Co.; 1996;p. 330–396
  5. Friedland IR, Paris M, Shelton S, McCracken GH. Time–kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. J. Antimicrob. Chemother. 1994;34:231–237
  6. Gombert ME, Aulicino TM. Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin. Antimicrob. Agents Chemother. 1984;26:933–934
  7. Jones RN. Should novobiocin be clinically re-evaluated?. Diagn. Microbiol. Infect. Dis. 1989;12:363–365
  8. Limson BM, Romansky MJ. Novobiocin, a new antibiotic; laboratory and clinical evaluation of thirty patients with bacterial pneumonia. Antibiotic Med. Clin. Ther. 1956;2:277–281
  9. Muñoz R, Bustamante M, de la Campa AG. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J. Bacteriol. 1995;177:4166–4170
  10. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin. Infect. Dis. 2009;48:e23–e33
  11. Sá Figueiredo AM, Austrian R, Urbaskova P, Teixeira LA, Tomasz A. Novel penicillin-resistant clones of Streptococcus pneumoniae in the Czech Republic and in Slovakia. Microb. Drug Res. 1995;1:71–78
  12. Shane SH. Novobiocin, a new antibiotic. Can. Med. Assoc. J. 1956;75:51–52
  13. Soriano F, Cafini F, Aguilar L, Tarragó D, Alou L, Giménez MJ, et al. Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness.. J. Antimicrob. Chemother. 2008;62:1234–1240
  14. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim–sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob. Agents Chemother. 1993;37:1334–1342
  15. Welch H, Lewis CN, Putnam LE, Randall WA. A study of the sensitizing potential of novobiocin. Antibiotic Med. Clin. Ther. 1956;3:27–32

PII: S0732-8893(09)00425-8

doi: 10.1016/j.diagmicrobio.2009.10.015

Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 3 , Pages 336-338 , March 2010

Article Tools